Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab + Azacitidine in HR-MDS
NCT06196203Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ligufalimab in myelodysplastic syndromes (MDS), sponsored by Akeso, Inc.. Started Feb 2024; status: recruiting.
02
Drugs
ligufalimab
03
Conditions
myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06196203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196203.